| scholarly article | Q13442814 |
| P50 | author | Stefan Engelter | Q50976682 |
| Mira Katan | Q51001422 | ||
| Ludwig Kappos | Q57912848 | ||
| Roland Bingisser | Q43190852 | ||
| Mirjam Christ-Crain | Q47139688 | ||
| P2093 | author name string | Andreas J Steck | |
| Beat Mueller | |||
| Felix Fluri | |||
| Marten Trendelenburg | |||
| Michael Osthoff | |||
| Philipp Schuetz | |||
| P2860 | cites work | Association Between Mannose-Binding Lectin Deficiency and Cytomegalovirus Infection After Kidney Transplantation | Q58075170 |
| Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the proenzyme C1r2C1s2 complex, of the classical pathway of complement, without involvement of C1q | Q68727641 | ||
| Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator | Q72893497 | ||
| Poor outcome after first-ever stroke: predictors for death, dependency, and recurrent stroke within the first year | Q78745314 | ||
| The differing roles of the classical and mannose-binding lectin complement pathways in the events following skeletal muscle ischemia-reperfusion | Q79370206 | ||
| Prognostic value of admission C-reactive protein in stroke patients undergoing iv thrombolysis | Q81289043 | ||
| Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury | Q81880380 | ||
| Systemic complement activation following human acute ischaemic stroke | Q47346589 | ||
| Mannose-binding lectin null alleles are associated with preserved epithelial cell integrity following intestinal ischemia reperfusion in man. | Q47706676 | ||
| High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke | Q48389128 | ||
| Recombinant C1 inhibitor in brain ischemic injury. | Q48444287 | ||
| Alterations in plasma complement levels after human ischemic stroke | Q48478044 | ||
| Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes. | Q48917743 | ||
| Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008 | Q57812917 | ||
| Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment | Q22306370 | ||
| C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells | Q24670661 | ||
| Acute-phase responsiveness of mannose-binding lectin in community-acquired pneumonia is highly dependent upon MBL2 genotypes | Q28244801 | ||
| Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. | Q30878935 | ||
| Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the 'Bergen stroke study'. | Q33436029 | ||
| Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke | Q33530136 | ||
| The role of the complement system in ischemia-reperfusion injury | Q34314080 | ||
| Complement: a novel factor in basal and ischemia-induced neurogenesis | Q34500822 | ||
| Mannose-binding lectin deficiency--revisited | Q35197925 | ||
| Mannan-binding lectin--a soluble pattern recognition molecule | Q35781824 | ||
| Mannose-binding lectin and its genetic variants. | Q36361610 | ||
| Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity | Q36486491 | ||
| C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death | Q37428732 | ||
| Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin | Q37430921 | ||
| Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention | Q38376259 | ||
| The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury | Q38782859 | ||
| Systemic inflammatory response depends on initial stroke severity but is attenuated by successful thrombolysis | Q40529322 | ||
| Progression in acute stroke: value of the initial NIH stroke scale score on patient stratification in future trials | Q40810789 | ||
| Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. | Q42610437 | ||
| The production of mannan-binding lectin is dependent upon thyroid hormones regardless of the genotype: a cohort study of 95 patients with autoimmune thyroid disorders. | Q43113080 | ||
| Copeptin: a novel, independent prognostic marker in patients with ischemic stroke | Q43207505 | ||
| Increased incidence and severity of the systemic inflammatory response syndrome in patients deficient in mannose-binding lectin | Q43725440 | ||
| Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury | Q43740164 | ||
| An assay for the mannan-binding lectin pathway of complement activation | Q43785256 | ||
| Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. | Q46477460 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | MBL deficiency | Q16994031 |
| P304 | page(s) | e21338 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients | |
| P478 | volume | 6 |
| Q47578520 | A New Surface Plasmon Resonance Assay for In Vitro Screening of Mannose-Binding Lectin Inhibitors. |
| Q34973359 | Cardioembolic and small vessel disease stroke show differences in associations between systemic C3 levels and outcome |
| Q88416950 | Changes in the Lectin Pathway Following Intracerebral or Spontaneous Subarachnoid Hemorrhage |
| Q47883886 | Combination Therapy with Low-Dose IVIG and a C1-esterase Inhibitor Ameliorates Brain Damage and Functional Deficits in Experimental Ischemic Stroke |
| Q26796057 | Complement in the Homeostatic and Ischemic Brain |
| Q36485729 | Early ficolin-1 is a sensitive prognostic marker for functional outcome in ischemic stroke |
| Q87979816 | Genetic Variation, Magnesium Sulfate Exposure, and Adverse Neurodevelopmental Outcomes Following Preterm Birth |
| Q35008490 | Human mannose-binding lectin inhibitor prevents myocardial injury and arterial thrombogenesis in a novel animal model |
| Q38164341 | If there is an evolutionary selection pressure for the high frequency of MBL2 polymorphisms, what is it? |
| Q91687521 | Immunomodulatory Therapeutic Strategies in Stroke |
| Q37413246 | Impact of mannose-binding lectin deficiency on radiocontrast-induced renal dysfunction |
| Q34400562 | Impact of mannose-binding lectin deficiency on radiocontrast-induced renal dysfunction: a post-hoc analysis of a multicenter randomized controlled trial |
| Q38978527 | Inflammation and Stroke: An Overview |
| Q47338117 | Inhibition of Complement Drives Increase in Early Growth Response Proteins and Neuroprotection Mediated by Salidroside After Cerebral Ischemia. |
| Q38991032 | Injury site-specific targeting of complement inhibitors for treating stroke |
| Q37703122 | Lectin Pathway of Complement Activation Is Associated with Vulnerability of Atherosclerotic Plaques |
| Q35857874 | Low ficolin-3 levels in early follow-up serum samples are associated with the severity and unfavorable outcome of acute ischemic stroke |
| Q40760025 | Low levels of mannose-binding lectin at admission increase the risk of adverse neurological outcome in preterm infants: a 1-year follow-up study |
| Q48606674 | MBL2 gene polymorphisms increase the risk of adverse neurological outcome in preterm infants: a preliminary prospective study. |
| Q37221426 | Mannan binding lectin-associated serine protease-2 (MASP-2) critically contributes to post-ischemic brain injury independent of MASP-1 |
| Q50852327 | Mannan-binding lectin deficiency attenuates acute GvHD in pediatric hematopoietic stem cell transplantation. |
| Q33616097 | Mannan-binding lectin in cardiovascular disease |
| Q37532531 | Mannan-binding lectin-associated serine protease 2 is critical for the development of renal ischemia reperfusion injury and mediates tissue injury in the absence of complement C4. |
| Q57786760 | Mannose-Binding Lectin Drives Platelet Inflammatory Phenotype and Vascular Damage After Cerebral Ischemia in Mice via IL (Interleukin)-1α |
| Q82831643 | Mannose-binding lectin-the forgotten molecule? |
| Q54988763 | Microglial Lectins in Health and Neurological Diseases. |
| Q89947833 | No association of complement mannose-binding lectin deficiency with cardiovascular disease in patients with Systemic Lupus Erythematosus |
| Q33948267 | No effect of ablation of surfactant protein-D on acute cerebral infarction in mice |
| Q64072728 | Novel MASP-2 inhibitors developed via directed evolution of human TFPI1 are potent lectin pathway inhibitors |
| Q44400729 | Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases. |
| Q34687497 | Potential role of the lectin pathway of complement in the pathogenesis and disease manifestations of systemic sclerosis: a case-control and cohort study |
| Q44543879 | Prognostic value of mannose-binding lectin: 90-day outcome in patients with acute ischemic stroke |
| Q38842752 | Protective action of B1R antagonist against cerebral ischemia-reperfusion injury through suppressing miR-200c expression of Microglia-derived microvesicles |
| Q64078418 | Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: a cross-sectional study |
| Q40961686 | Serum mannose-binding lectin levels after aneurysmal subarachnoid hemorrhage |
| Q56484686 | Serum protein biomarkers screening in patients with ischemic stroke by LC-MS/MS |
| Q92987432 | Specific contribution of mannose-binding lectin murine isoforms to brain ischemia/reperfusion injury |
| Q85893127 | TFPI inhibits lectin pathway of complement activation by direct interaction with MASP-2 |
| Q36340412 | Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia. |
| Q92239487 | The Human Platelet as an Innate Immune Cell: Interactions Between Activated Platelets and the Complement System |
| Q36339354 | The alternative complement pathway propagates inflammation and injury in murine ischemic stroke |
| Q44205820 | The relationship between serum mannose-binding lectin levels and acute ischemic stroke risk |
| Q92650436 | Therapeutic Modulation of the Complement Cascade in Stroke |
| Q34471200 | Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis |
Search more.